Hypermarcas (HYPMY) Set to Announce Quarterly Earnings on Wednesday

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) will likely be releasing its results after the market closes on Wednesday, November 11th. Analysts expect Hypermarcas to announce earnings of $0.14 per share and revenue of $450.75 million for the quarter.

Hypermarcas Trading Up 2.1%

Shares of HYPMY stock opened at $4.11 on Tuesday. The company has a 50 day moving average of $4.64 and a 200-day moving average of $4.41. The company has a quick ratio of 1.26, a current ratio of 1.86 and a debt-to-equity ratio of 0.50. Hypermarcas has a 12-month low of $3.39 and a 12-month high of $5.77. The firm has a market cap of $2.89 billion, a P/E ratio of 7.80 and a beta of 0.78.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group raised shares of Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy”.

View Our Latest Research Report on HYPMY

Hypermarcas Company Profile

(Get Free Report)

Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories.

Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo QuĂ­mica and Mantecorp.

The company is based in Brazil and serves the domestic market through its pharmaceutical operations.

Further Reading

Earnings History for Hypermarcas (OTCMKTS:HYPMY)

Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.